Paris-based Sanofi bought Cambridge, Massachusetts-based Tidal Therapeutics in a deal totaling $470 million.
Thermo Fisher Scientific is acquiring Mesa Biotech for about $450 million in cash, and will pay an additional $100 million in cash after certain milestones are hit.
Biogen will take a $650 million stake in Sage Therapeutics and make an upfront payment of $875 million to jointly develop and sell treatments for depression and other neurological disorders.
With a $425 million upfront payment, Bayer bolstered the company’s women’s healthcare pipeline with the acquisition of U.K.-based KaNDy Therapeutics and an investigational treatment for menopause.
Kiadis Pharma licensed a previously undisclosed K-NK0004 program to Sanofi covering Kiadis’ proprietary CD38 knock out (CD38KO) K-NK therapeutics for combination with anti-CD38 monoclonal antibodies.
Sanofi Pasteur and Lexington, Massachusetts-based Translate Bio announced the expansion of an existing collaboration to develop mRNA vaccines for infectious diseases.
Shares of Voyager Therapeutics skyrocketed after the company announced a collaborative deal to develop a gene therapy treatment for Parkinson’s disease with Neurocrine Biosciences.
Alkermes, headquartered in Dublin, Ireland, received a $50 million milestone payment from Cambridge, Massachusetts-based Biogen.